Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 6:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 1,037 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: dietary sodium Clear all
Terminated Early Phase 1 Interventional Accepts healthy volunteers

SALT: Alternative Donor Bone Marrow and Cord Blood Transplantation for High Risk Sickle Cell Disease

NCT00257543
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Alternative donor bone marrow and cord blood
Procedure
Lead sponsor
Emory University
Other
Eligibility
Up to 16 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 17, 2013 · Synced Oct 16, 2026, 6:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C -GSK1322322 After an Intravenous and an Oral Dose

NCT01663389
View directory record Official record
Conditions
Infections, Bacterial
Interventions
GSK1322322 1000 mg containing radioactive 14C-GSK1322322, GSK1322322 1200 mg containing radioactive 14C-GSK1322322
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years to 55 Years · Male only
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 12, 2017 · Synced Oct 16, 2026, 6:51 AM EDT
Completed Phase 1 Interventional

Sorafenib in Treating Patients With Recurrent or Progressive Malignant Glioma

NCT00093613
View directory record Official record
Conditions
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
Interventions
sorafenib tosylate, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
10
States / cities
Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated May 30, 2014 · Synced Oct 16, 2026, 6:51 AM EDT
Completed Phase 4 Interventional Results available

To Evaluate the Effect of Liraglutide on Ambulatory Blood Pressure-A Pilot Study

NCT02299388
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent, Hypertensive Disease
Interventions
Liraglutide or Placebo
Drug
Lead sponsor
Tulane University School of Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Oct 16, 2026, 6:51 AM EDT
Completed Phase 2 Interventional Results available

Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer

NCT00253370
View directory record Official record
Conditions
Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancer, Advanced Unresectable Gastric Cancer
Interventions
BAY 43-9006, docetaxel, cisplatin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 24, 2014 · Synced Oct 16, 2026, 6:51 AM EDT
Active, not recruiting Phase 3 Interventional

Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

NCT04092283
View directory record Official record
Conditions
Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma
Interventions
Carboplatin, Cisplatin, Durvalumab, Etoposide, Paclitaxel, Pemetrexed Disodium
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
829
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Gilbert, Arizona + 549 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 16, 2026, 6:51 AM EDT
Completed Phase 3 Interventional

Sodium Lowering and Urinary Protein Reduction Trial

NCT02945969
View directory record Official record
Conditions
Chronic Kidney Disease, Albuminuria
Interventions
Low Sodium Diet
Behavioral
Lead sponsor
Tulane University School of Public Health and Tropical Medicine
Other
Eligibility
21 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Oct 16, 2026, 6:51 AM EDT
Completed Phase 1 Interventional

Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors

NCT02631733
View directory record Official record
Conditions
Malignant Solid Neoplasm
Interventions
Ferumoxytol, Irinotecan Sucrosofate, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Veliparib
Drug · Other · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
6
States / cities
Baltimore, Maryland • Bethesda, Maryland • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Oct 16, 2026, 6:51 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

ABC294640 (Opaganib) in Refractory / Relapsed Multiple Myeloma

NCT02757326
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Opaganib
Drug
Lead sponsor
RedHill Biopharma Limited
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 18, 2021 · Synced Oct 16, 2026, 6:51 AM EDT
Completed Phase 1Phase 2 Interventional

Novel Drug Delivery Technique Via Retroject Device

NCT02051946
View directory record Official record
Conditions
Glaucoma
Interventions
Retroject Device, ethacrynic acid injection, balanced salt solution
Device · Drug
Lead sponsor
Molly Walsh
Other
Eligibility
55 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 17, 2017 · Synced Oct 16, 2026, 6:51 AM EDT
Suspended Phase 2 Interventional

Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery

NCT06050252
View directory record Official record
Conditions
Resectable Intrahepatic Cholangiocarcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Cisplatin, Computed Tomography, Durvalumab, Gemcitabine, Magnetic Resonance Imaging, Resection
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
57
States / cities
Irvine, California • Los Angeles, California • Orange, California + 47 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 16, 2026, 6:51 AM EDT
Completed Not applicable Interventional Results available

Dietary Nitrates and Vascular Function in Patients With Peripheral Artery Disease

NCT01983826
View directory record Official record
Conditions
Peripheral Artery Disease
Interventions
Sodium Nitrate, Placebo
Dietary Supplement · Other
Lead sponsor
University of Iowa
Other
Eligibility
50 Years to 85 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jun 3, 2019 · Synced Oct 16, 2026, 6:51 AM EDT
Terminated Phase 4 Interventional Results available

Suprainguinal Fascia Iliaca (SIFI) Block Improves Analgesia Following Total Hip Arthroplasty

NCT02933671
View directory record Official record
Conditions
Hip Osteoarthritis, Primary Total Hip Arthroplasty, Pain
Interventions
Suprainguinal fascia iliaca (SIFI) block, Sham block, Ropivacaine, Saline
Procedure · Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 19, 2022 · Synced Oct 16, 2026, 6:51 AM EDT
Active, not recruiting Phase 1 Interventional Results available

Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate

NCT03582475
View directory record Official record
Conditions
Bladder Small Cell Neuroendocrine Carcinoma, Castration-Resistant Prostate Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Prostate Carcinoma Metastatic in the Bone, Prostate Neuroendocrine Neoplasm, Prostate Small Cell Carcinoma, Stage III Bladder Cancer American Joint Committee on Cancer ( AJCC) v8, Stage III Prostate Cancer AJCC v8, Stage III Urethral Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8, Stage IVA Bladder Cancer AJCC v8, Stage IVB Bladder Cancer AJCC v8, Ureter Small Cell Carcinoma, Urothelial Carcinoma
Interventions
Carboplatin, Cisplatin, Docetaxel, Etoposide, Pembrolizumab
Drug · Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 16, 2026, 6:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics and Bioequivalence of Sumatriptan Delivered Via the Intraject System

NCT00614029
View directory record Official record
Conditions
Pharmacokinetics, Bioequivalence
Interventions
Sumatriptan (via Intraject System)
Device
Lead sponsor
Zogenix, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 10, 2022 · Synced Oct 16, 2026, 6:51 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Dopamine in Orthostatic Tolerance

NCT00748228
View directory record Official record
Conditions
Postural Tachycardia Syndrome
Interventions
dietary sodium
Dietary Supplement
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 60 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 15, 2015 · Synced Oct 16, 2026, 6:51 AM EDT
Not listed Phase 3 Interventional

Corneal Collagen Crosslinking for Progressive Keratoconus and Ectasia Using Riboflavin/Dextran and Hypotonic Riboflavin

NCT01152541
View directory record Official record
Conditions
Keratoconus, Corneal Ectasia
Interventions
Riboflavin/Dextran, Hypotonic Riboflavin
Drug
Lead sponsor
Cornea and Laser Eye Institute
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2025
U.S. locations
1
States / cities
Teaneck, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 16, 2026, 6:51 AM EDT
Not listed Phase 1Phase 2 Interventional

Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma

NCT00293475
View directory record Official record
Conditions
Central Nervous System Lymphoma
Interventions
Carboplatin, Mannitol, Methotrexate, Quality-of-Life Assessment, Rituximab, Sodium Thiosulfate
Drug · Other · Biological
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2023
U.S. locations
4
States / cities
Cincinnati, Ohio • Cleveland, Ohio • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2021 · Synced Oct 16, 2026, 6:51 AM EDT
Active, not recruiting Not applicable Interventional

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

NCT02194738
View directory record Official record
Conditions
Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Carboplatin, Cisplatin, Clinical Observation, Computed Tomography, Crizotinib, Cytology Specimen Collection Procedure, Echocardiography Test, Erlotinib, Gemcitabine Hydrochloride, Nivolumab, Paclitaxel, Pembrolizumab, Pemetrexed, Pemetrexed Disodium, Placebo Administration, Positron Emission Tomography
Procedure · Drug · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
7,458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1655
States / cities
Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 1013 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 16, 2026, 6:51 AM EDT
Terminated Phase 2 Interventional Results available

Bintrafusp Alfa With Chemotherapy for Tyrosine Kinase Inhibitor-Resistant EGFR-Mutant Non-small Cell Lung Cancer

NCT04971187
View directory record Official record
Conditions
Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Unresectable Lung Non-Squamous Non-Small Cell Carcinoma
Interventions
Bintrafusp Alfa, Pemetrexed, Carboplatin, Cisplatin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Oct 16, 2026, 6:51 AM EDT
Completed Not applicable Interventional

Impact of a Personal Digital Assistant (PDA) - Based Dietary Adherence Intervention on Interdialytic Weight Gain and Blood Pressure in Hemodialysis Patients

NCT00447408
View directory record Official record
Conditions
End-Stage Renal Disease
Interventions
Standard hemodialysis dietary instruction, Behavioral counseling plus PDA-based self-monitoring of diet
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
21 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 28, 2010 · Synced Oct 16, 2026, 6:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Examining the Differential Effects of Traditional Float-REST and Dry Float on Subjective and Objective Health Outcomes

NCT04628910
View directory record Official record
Conditions
Sleep Quality
Interventions
Simulated Flotation Therapy, Traditional Float-REST Therapy
Other
Lead sponsor
West Virginia University
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Oct 16, 2026, 6:51 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies

NCT04172597
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Solid Tumor, Glioblastome Multiforme
Interventions
Poziotinib Hydrochloride, Loperamide
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Mar 13, 2024 · Synced Oct 16, 2026, 6:51 AM EDT
Completed Phase 2 Interventional Results available

FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer

NCT02890355
View directory record Official record
Conditions
Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage IV Pancreatic Cancer AJCC v6 and v7
Interventions
Fluorouracil, Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Leucovorin Calcium, Veliparib
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
783
States / cities
Mobile, Alabama • Anchorage, Alaska • Hot Springs, Arkansas + 507 more
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 16, 2026, 6:51 AM EDT